Trial Profile
Efficacy and tolerability of levofloxacin [MP 376] for the prevention of acute exacerbations in high-risk patients with chronic obstructive pulmonary disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2012
Price :
$35
*
At a glance
- Drugs Levofloxacin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 20 Jul 2012 New trial record